Intellia (NTLA) FDA accepts Lonvo-z BLA for hereditary angioedema
Intellia Therapeutics said the FDA accepted its biologics license application for Lonvoguran ziclumeran (Lonvo-z) for hereditary angioedema and granted priority review.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.